vs
Side-by-side financial comparison of ENANTA PHARMACEUTICALS INC (ENTA) and JOINT Corp (JYNT). Click either name above to swap in a different company.
ENANTA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($18.6M vs $15.2M, roughly 1.2× JOINT Corp). JOINT Corp runs the higher net margin — 6.5% vs -64.1%, a 70.7% gap on every dollar of revenue. On growth, ENANTA PHARMACEUTICALS INC posted the faster year-over-year revenue change (9.8% vs 3.1%). JOINT Corp produced more free cash flow last quarter ($334.7K vs $-11.8M). Over the past eight quarters, ENANTA PHARMACEUTICALS INC's revenue compounded faster (4.5% CAGR vs -28.6%).
Enanta Pharmaceuticals Inc is a clinical-stage biotechnology company that develops innovative antiviral therapies for infectious diseases including hepatitis B virus, respiratory syncytial virus (RSV), and SARS-CoV-2. It operates primarily in the U.S. and global markets, partnering with pharmaceutical firms to advance its small molecule drug candidate pipeline for patients with unmet medical needs.
The Joint Corp is a leading operator and franchisor of chiropractic care clinics primarily serving the U.S. market. It offers accessible, affordable routine chiropractic services, membership-based care plans, and caters to consumers seeking non-invasive musculoskeletal pain management and wellness support.
ENTA vs JYNT — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.6M | $15.2M |
| Net Profit | $-11.9M | $991.1K |
| Gross Margin | — | 81.4% |
| Operating Margin | -60.5% | 4.9% |
| Net Margin | -64.1% | 6.5% |
| Revenue YoY | 9.8% | 3.1% |
| Net Profit YoY | 46.4% | 5510.5% |
| EPS (diluted) | $-0.42 | $0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $18.6M | $15.2M | ||
| Q3 25 | $15.1M | $13.4M | ||
| Q2 25 | $18.3M | $13.3M | ||
| Q1 25 | $14.9M | $13.1M | ||
| Q4 24 | $17.0M | $14.7M | ||
| Q3 24 | $14.6M | $30.2M | ||
| Q2 24 | $18.0M | $30.3M | ||
| Q1 24 | $17.1M | $29.7M |
| Q4 25 | $-11.9M | $991.1K | ||
| Q3 25 | $-18.7M | $855.0K | ||
| Q2 25 | $-18.3M | $93.4K | ||
| Q1 25 | $-22.6M | $967.8K | ||
| Q4 24 | $-22.3M | $17.7K | ||
| Q3 24 | $-28.8M | $-3.2M | ||
| Q2 24 | $-22.7M | $-3.6M | ||
| Q1 24 | $-31.2M | $947.0K |
| Q4 25 | — | 81.4% | ||
| Q3 25 | — | 80.1% | ||
| Q2 25 | — | 79.1% | ||
| Q1 25 | — | 77.3% | ||
| Q4 24 | — | 78.4% | ||
| Q3 24 | — | 90.7% | ||
| Q2 24 | — | 90.7% | ||
| Q1 24 | — | 90.9% |
| Q4 25 | -60.5% | 4.9% | ||
| Q3 25 | -121.6% | 1.2% | ||
| Q2 25 | -103.2% | -8.6% | ||
| Q1 25 | -164.3% | -5.2% | ||
| Q4 24 | -138.8% | 5.5% | ||
| Q3 24 | -204.4% | -1.6% | ||
| Q2 24 | -134.6% | -5.9% | ||
| Q1 24 | -192.1% | -1.4% |
| Q4 25 | -64.1% | 6.5% | ||
| Q3 25 | -123.6% | 6.4% | ||
| Q2 25 | -99.7% | 0.7% | ||
| Q1 25 | -151.7% | 7.4% | ||
| Q4 24 | -131.4% | 0.1% | ||
| Q3 24 | -197.3% | -10.5% | ||
| Q2 24 | -126.1% | -11.9% | ||
| Q1 24 | -182.7% | 3.2% |
| Q4 25 | $-0.42 | $0.06 | ||
| Q3 25 | $-0.88 | $0.06 | ||
| Q2 25 | $-0.85 | $0.01 | ||
| Q1 25 | $-1.06 | $0.06 | ||
| Q4 24 | $-1.05 | $0.01 | ||
| Q3 24 | $-1.36 | $-0.21 | ||
| Q2 24 | $-1.07 | $-0.24 | ||
| Q1 24 | $-1.47 | $0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | $23.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $126.6M | $15.1M |
| Total Assets | $329.5M | $61.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $37.4M | $23.6M | ||
| Q3 25 | $32.3M | $29.7M | ||
| Q2 25 | $44.8M | $29.8M | ||
| Q1 25 | $60.2M | $21.9M | ||
| Q4 24 | $84.3M | $25.1M | ||
| Q3 24 | $37.2M | $20.7M | ||
| Q2 24 | $35.8M | $17.5M | ||
| Q1 24 | $63.5M | $18.7M |
| Q4 25 | $126.6M | $15.1M | ||
| Q3 25 | $64.7M | $22.7M | ||
| Q2 25 | $79.3M | $23.2M | ||
| Q1 25 | $93.5M | $22.8M | ||
| Q4 24 | $111.8M | $20.7M | ||
| Q3 24 | $128.8M | $20.5M | ||
| Q2 24 | $148.9M | $23.2M | ||
| Q1 24 | $166.1M | $26.2M |
| Q4 25 | $329.5M | $61.0M | ||
| Q3 25 | $280.7M | $69.4M | ||
| Q2 25 | $301.0M | $73.2M | ||
| Q1 25 | $323.0M | $80.1M | ||
| Q4 24 | $348.6M | $83.2M | ||
| Q3 24 | $376.7M | $79.6M | ||
| Q2 24 | $398.8M | $82.4M | ||
| Q1 24 | $413.6M | $85.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-11.7M | $1.8M |
| Free Cash FlowOCF − Capex | $-11.8M | $334.7K |
| FCF MarginFCF / Revenue | -63.6% | 2.2% |
| Capex IntensityCapex / Revenue | 0.8% | 9.9% |
| Cash ConversionOCF / Net Profit | — | 1.86× |
| TTM Free Cash FlowTrailing 4 quarters | $-18.5M | $-1.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-11.7M | $1.8M | ||
| Q3 25 | $-6.5M | $1.8M | ||
| Q2 25 | $17.5M | $868.6K | ||
| Q1 25 | $-13.5M | $-3.7M | ||
| Q4 24 | $-16.8M | $9.4M | ||
| Q3 24 | $-10.4M | $3.4M | ||
| Q2 24 | $-14.8M | $-973.5K | ||
| Q1 24 | $-28.6M | $2.8M |
| Q4 25 | $-11.8M | $334.7K | ||
| Q3 25 | $-7.9M | $1.5M | ||
| Q2 25 | $17.4M | $363.6K | ||
| Q1 25 | $-16.0M | $-4.0M | ||
| Q4 24 | $-25.5M | $8.2M | ||
| Q3 24 | $-19.4M | $3.2M | ||
| Q2 24 | $-21.3M | $-1.2M | ||
| Q1 24 | $-30.3M | $2.4M |
| Q4 25 | -63.6% | 2.2% | ||
| Q3 25 | -52.5% | 10.9% | ||
| Q2 25 | 94.7% | 2.7% | ||
| Q1 25 | -107.4% | -30.8% | ||
| Q4 24 | -150.6% | 55.9% | ||
| Q3 24 | -132.5% | 10.6% | ||
| Q2 24 | -118.6% | -4.1% | ||
| Q1 24 | -177.5% | 8.1% |
| Q4 25 | 0.8% | 9.9% | ||
| Q3 25 | 9.6% | 2.4% | ||
| Q2 25 | 0.8% | 3.8% | ||
| Q1 25 | 17.0% | 2.5% | ||
| Q4 24 | 51.6% | 8.1% | ||
| Q3 24 | 61.3% | 0.8% | ||
| Q2 24 | 36.4% | 0.9% | ||
| Q1 24 | 9.8% | 1.3% |
| Q4 25 | — | 1.86× | ||
| Q3 25 | — | 2.07× | ||
| Q2 25 | — | 9.30× | ||
| Q1 25 | — | -3.82× | ||
| Q4 24 | — | 532.98× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 2.97× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ENTA
Segment breakdown not available.
JYNT
| Transferred At Point In Time | $12.8M | 84% |
| Transferred Over Time | $2.4M | 16% |
